Abzena provides technologies and complementary services across Biology, Chemistry and Manufacturing.

Abzena announces a research and licence agreement with Tmunity Therapeutics

a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers

Release of first GMP drug substance for an ABZENA Inside product manufactured by Abzena

The manufacture of this product took place at Abzena’s site in San Diego, CA but utilised significant bioanalytics and bioassay expertise from Abzena’s Cambridge, UK site including product characterisation, binding, potency and stability assays.

Abzena and Telix sign licence agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Under the terms of the Agreement, Abzena has granted Telix an exclusive worldwide, royalty bearing, sub-licensable licence to its prostate-specific membrane antigen (‘PSMA’) antibodies in the field of radio-immunoconjugation.